Covered recipient · General Payments record
YESHANEW TEKLIE
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2022–2024
$1,292.45
- Reported across 26 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $417.15 | 8 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $145.94 | 1 |
| Blueprint Medicines Corporation | $118.40 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $33.66 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.09 | 1 |
| Merck Sharp & Dohme Corporation | $26.69 | 1 |
| Karyopharm Therapeutics Inc. | $25.74 | 1 |
| ABBVIE INC. | $21.70 | 1 |
| Alexion Pharmaceuticals, Inc. | $16.93 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (8)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.70 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106208831 | CMS |
| Alexion Pharmaceuticals, Inc. | $16.93 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110512182 | CMS |
| Blueprint Medicines Corporation | $118.40 | 06/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147443604 | CMS |
| Janssen Biotech, Inc. | $145.94 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078484496 | CMS |
| Karyopharm Therapeutics Inc. | $25.74 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145538043 | CMS |
| Merck Sharp & Dohme LLC | $26.69 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141581109 | CMS |
| Novartis Pharmaceuticals Corporation | $33.66 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087441420 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.09 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137686760 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.